Abstract
Although disease free survival (DFS) is not a validated surrogate endpoint for overall survival (OS) in most breast cancer subtypes, regulatory approvals based on DFS are common. The objective of this study was to assess the changes in the type of events contributing to DFS over time.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
